One Premarket Route in Guatemala: No Abbreviated Device Pathway

1. Key takeaways

The premarket pathway for medical devices and in vitro diagnostic reagents in Guatemala is a single route: the sanitary registration is submitted under NT-37 v5-2016 for devices or NT-40 v3-2015 for reagents. The clause structure of these two official standards contains no provision for a fast track split by risk category, for a reliance pathway that leans on the approval of another regulatory authority, or for an abbreviated procedure triggered by approvals granted in other countries. A product that has already been approved in the United States, the European Union or Canada does not, by that fact alone, qualify for accelerated treatment in Guatemala. The regulatory design is deliberately uniform: every device and every reagent enters the market through the same sanitary registration procedure, and the only legitimate variable is the depth of the dossier and the testing obligation that the product’s classification imposes. Any project plan that assumes a shortcut exists is built on a premise the legal texts do not support.

2. Legal basis

The following provisions define the single-route structure and clarify where the simplified mechanisms that do exist in Guatemalan law actually apply.

3. Expert insights

Insight one: the simplified mechanisms all sit on the pharmaceutical side and have not been extended to devices. Guatemala does have two kinds of simplified arrangements, namely the sworn declaration channel of Acuerdo Gubernativo 104-2018 for pharmaceutical products already approved by eight authorities, and the generic-to-brand simplified procedure of NT 57 v02-2023. Both instruments apply to pharmaceuticals; neither NT-37 nor NT-40 contains any corresponding clause. Transposing the pharmaceutical-side conveniences onto devices is the single most common source of planning errors, because the analogy looks plausible on the surface and is only disproved by reading the actual texts of the device and reagent standards.

Insight two: classification affects testing, not the pathway. Annex 1 of NT-37 places the testing obligation directly beneath the class headings: Class I is exempt from testing, while Classes II to IV require physicochemical and microbiological testing. This is a difference in dossier depth within the same pathway, not a choice between two pathways. Third-party compilations describe Guatemala in the same terms, noting a single procedure with no category-specific, accelerated or reference-authority variants, which is consistent with the structure of the official texts and reinforces the reading set out above.

Insight three: reference-country approvals serve as evidence, not as a channel. An approval already obtained in the United States or the European Union can support the dossier at the documentary level, for example through the certificate of manufacturing guarantee (Article 5.1.6 and Article 6.12.6 of NT-37 both list the FDA as one of the acceptable sources of evidence for manufacturing guarantee), but it cannot compress the intensity of the review as a whole. Treating the situation as «an FDA approval means exemption from review» leads to deficiency requests when the remaining dossier items are incomplete, because the reviewer will still examine every element the standard requires and will issue a formal request for correction where anything is missing.

Insight four: regional harmonisation aligns the dossiers, not the approvals. The Central American technical regulations (RTCA) bring the dossier structures and requirements of the six countries closer together, but each country still receives, fees and issues certificates separately. One regional harmonisation exercise does not equal one registration that grants access to all six markets; each market still requires its own application, its own fee and its own certificate before the product can be placed on it.

Taken together, these four insights describe a regulatory system that is simpler in structure than many neighbouring jurisdictions but stricter in its uniformity. The single pathway concentrates all discretion in one set of dossier requirements and one review process, which rewards applicants who read the two standards closely and punishes assumptions imported from other markets. A sponsor preparing a Guatemalan submission should therefore anchor the project plan to the letter of NT-37 or NT-40, treat every foreign approval as a document to be filed rather than a privilege to be claimed, and verify at the planning stage that no product in the portfolio requires anything other than the standard sanitary registration procedure.

4. Practical recommendations

• Schedule the project around a single pathway, and do not reserve process milestones for an acceleration that does not exist.
• Position foreign approvals as supporting evidence, file them under the certificate of manufacturing guarantee pursuant to Article 5.1.6 of NT-37, and do not let them substitute for other dossier items.
• Once classification is determined, immediately establish whether testing is required and fold the testing schedule into the master plan.
• Plan multi-country Central American projects on the basis of one dossier, separate applications, with separate scheduling and budgeting for the six countries.
• Monitor whether the 2026 new regulation (G/TBT/N/GTM/106, intended to enter into force 2026-12-01) introduces new pathways, taking the official gazette as authoritative.

5. Verification checklist

• □ The project has been scheduled on a single pathway, with no acceleration milestones reserved
• □ Foreign approvals have been positioned as supporting evidence rather than as a pathway
• □ The testing obligation attached to the product’s class has been confirmed
• □ Multi-country projects have been planned as separate applications
• □ A monitoring item has been logged for pathway changes under the 2026 new regulation

Regulatory information verified as of 29 October 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Guatemalan market. Our team manages Ministry of Public Health and Social Assistance (MSPAS) registrations, coordinates import and distributor requirements, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com